Results 181 to 190 of about 115,857 (253)

On the prenatal origins of the myeloproliferative neoplasms. [PDF]

EXCLI J
Langabeer SE.
europepmc   +1 more source

Microbiota-Inflammation Crosstalk in Myeloproliferative Neoplasms: MPN-Specific Human Data, Mechanistic Plausibility and Translational Priorities. [PDF]

Biomedicines
Țîrlea LG, Lipan L, Tănase AD.
europepmc   +1 more source

Clinical Associations of Osteoporosis in BCR::ABL1 Negative Myeloproliferative Neoplasms. [PDF]

Int J Endocrinol
Aydin MS, Dagdas S, Pepeler MS, Korkmaz G, Alper A, Açıkgöz E, Bektas TN, Pamukçuoğlu M, Ceran F, Ozet G.   +9 more
europepmc   +1 more source

Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting. [PDF]

Exp Hematol Oncol
Zhang T, Jiang H, Liu D.
europepmc   +1 more source

Prognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates. [PDF]

Cancers (Basel)
Al-Zubaidi N, Ruiz E, Curto-Garcia N, Sriskandarajah P.   +3 more
europepmc   +1 more source

Optimized Test Utilization Significantly Increased the Positive Detection Rate for Myeloproliferative Neoplasms. [PDF]

Cancers (Basel)
Nfonsam LE, Qi MZ, Butcher DT, Campbell CJV, Cocca A, Dalmia S, Davies GA, Hohenadel BA, McCready E.   +8 more
europepmc   +1 more source

BCL-XL drives fibrotic and leukemic progression in myeloproliferative neoplasms. [PDF]

Front Immunol
Wu C, Wang Y, Zhang Q, Li C, Chen Y, Wu Y.   +5 more
europepmc   +1 more source

Molecular and Functional Platelet Abnormalities in Myeloproliferative Neoplasms. [PDF]

Cells
Wang AX, Guo BB, Linden MD.
europepmc   +1 more source

Mutant calreticulin-directed immunotherapies in myeloproliferative neoplasms. [PDF]

Blood Neoplasia
Heaton WL, Jenkins MT, Arellano NS, Brown CT, Tantravahi SK, Elf SE.   +5 more
europepmc   +1 more source